Predictors of Morbidity and Mortality in Neonates with Herpes Simplex Virus Infections

摘要: Background In a controlled trial comparing acyclovir with vidarabine in the treatment of neonatal herpes simplex virus (HSV) infection, we found no significant difference between treatments adjusted mortality and morbidity. Hence, sought to define for entire cohort (n = 202) clinical characteristics that best predicted eventual outcome these neonates. Methods Data were gathered prospectively at 27 centers 1981 1988 infants less than one month age who had virologically confirmed HSV infection. We examined outcomes by multivariate analyses 24 variables. Disease was classified three categories based on extent involvement entry into trial: infection confined skin, eyes, or mouth; encephalitis; disseminated Results conclusions There deaths among 85 localized The rate significantly higher 46 neonates (57 percent) 71 encephalitis (15 percent). addition, risk death increased near coma (relative risk, 5.2), intravascular coagulopathy 3.8), premature 3.7). babies disease, pneumonitis also associated greater 3.6). survivors, morbidity most frequent 4.4), 2.1), seizures 3.0), type 2 4.9). With limited mouth, presence more recurrences vesicles an neurologic impairment as compared two fewer recurrences.